Skip to main content
SpringerLink
Log in

Watanidipine

AE 0047, Calbren®, GJ 0956, Vatanidipine

  • Research Review
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. 1This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Hayashi K, Gohda M, Matzno S, Kubo Y, Kido H, et al. Possible mechanism of action of AE0047, a calcium antagonist, on triglyceride metabolism. Journal of Pharmacology and Experimental Therapeutics 282: 882–890, Aug 1997

    PubMed  CAS  Google Scholar 

  2. Azuma J, Harada H, Kurimoto T, et al. Phase I study of GJ-0956, Ca antagonist. Rinsho Iyaku 13: 2121–2144, No. 9, 1997

    Google Scholar 

  3. Ogihara T, Higaki J, Aoki T, et al. Pharmacokinetic study of GJ-0956 (watanidipine hydrochloride) in elderly healthy people. Rinsho Iyaku 13: 2159–2167, No. 9, 1997

    Google Scholar 

  4. Kaku T, Suzuki S, Yano K, et al. Pharmacokinetic study of GJ-0956 (watanidipine hydrochloride) in patients with essential hypertension. Rinsho Iyaku 13: 2887–2905, No. 11, 1997

    Google Scholar 

  5. Takeda T, Iimura O, Abe K, et al. Efficacy and safety of GJ-0956 monotherapy in patients with essential hypertension: a late phase II study for evaluation of optimum dose. Rinsho Iyaku 13: 2213–2236, No. 9, 1997

    Google Scholar 

  6. Takeda T, Iimura O, Abe K, et al. Efficacy and safety of GJ-0956 in combination with diuretic or beta-blocker in patients with essential hypertension. Rinsho Iyaku 13: 2237–2264, No. 9, 1997

    Google Scholar 

  7. Takeda T, Saruta T, Abe K, et al. Antihypertensive effect, safety and usefulness of GJ-0956 in hypertensive patients with renal impairment. Rinsho Iyaku 13: 2429–2461, No. 9, 1997

    Google Scholar 

  8. Hayashi K, Imada T, Yamauchi T, Kido H, Shinyama H, et al. Possible mechanism for the anti-atherosclerotic action of the calcium channel blocker AE0047 in cholesterol-fed rabbits. Clinical & Experimental Pharmacology and Physiology 25: 17–25, Jan 1998

    Article  CAS  Google Scholar 

  9. Hayashi K, Uchida T, Kido H, Shinyama H, Watanabe M. Effects of AE0047 on renal haemodynamics and function in anaesthetized dogs. Clinical and Experimental Pharmacology and Physiology 20: 103–111, Feb 1993

    Article  PubMed  CAS  Google Scholar 

  10. Ohta Y, Chikugo T, Suzuki T. Long term therapeutic effects of ACE inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Clinical and Experimental Pharmacology and Physiology (Suppl 1): 103, 1994

    Google Scholar 

  11. Hayashi K, Uchida T, Kido H, et al. Diuretic effect and antiproteinuric effect of the novel calcium channel blocker AE0047. Japanese Journal of Pharmacology 64 (Suppl 1): 256, 1994

    Google Scholar 

  12. Hayashi K, Kido H, Kubo Y, Uchida T, Watanabe M. Uricosuric action of calcium channel blocker AE0047 in rats. Japanese Journal of Pharmacology 67 (Suppl I): 318, 1995

    Google Scholar 

  13. Ohta Y, Chikugo T-A, Suzuki T. Long-term therapeutic effects of ACE inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Clinical & Experimental Pharmacology and Physiology 22 (Suppl 1): 321–322, Dec 1995

    Article  Google Scholar 

  14. Ohtsuka K, Tsukiyama H, Ono Y, et al. Hemodynamic effect of the novel dihydropyridine calcium antagonist GJ-0956 (watanidipine hydrochloride) in essential hypertension. Rinsho Iyaku 13: 2347–2354, No. 9, 1997

    Google Scholar 

  15. Shinyama H, Nagai H, Kawamura T, et al. Effects of long-term antihypertensive treatment with AE0047, a novel Ca antagonist, on cerebrovascular autoregulation and hypertrophy in spontaneously hypertensive rats. Japanese Journal of Pharmacology 58 (Suppl 1): 405, 1992

    Google Scholar 

  16. Yamanaga K, Ohtaki Y, Uchida T, et al. Effect of a novel calcium antagonist AE0047 on several models of cerebral ischemia. Drug Development Research 26: 173–181, No. 2, 1992

    Article  CAS  Google Scholar 

  17. Shinyama H, Kawamura T, Nagai H, et al. A possible application of AE0047, a novel Ca antagonist for treatment of stroke. Japanese Journal of Pharmacology 61 (Suppl I): 132P, 1993

    Google Scholar 

  18. Kawamura T, Shinyama H, Narita Y, et al. Protective effect of AE0047, a novel Ca antagonist, on incidence of stroke in stroke-prone spontaneously hypertensive rats. Japanese Journal of Pharmacology 61 (Suppl I): 209P, 1993

    Google Scholar 

  19. Okita M, Shinyama H, Kawamura T, et al. Ameliorative effect of AE0047, a calcium channel blocker, on memory impairment after transient cerebral ischemia in rats. Japanese Journal of Pharmacology 64 (Suppl 1): 353, 1994

    Google Scholar 

  20. Takeda T, Iimura O, Abe K, et al. Clinical evaluation of GJ-0956 on essential hypertension: a double-blind comparative studywith nitrendipine. Rinsho Iyaku 13: 2907–2950, No. 11, 1997

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watanidipine. Drugs R&D 3, 331–336 (2002). https://doi.org/10.2165/00126839-200203050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203050-00007

Keywords

Search

Navigation